An oral hypoglycemic drug preparation and preparation method thereof
By forming a complex of polyphenol organic compounds and polypeptide drugs, the problem of oral GLP-1 receptor agonist is solved, the stability and absorption efficiency of the drug are improved, and the efficient oral hypoglycemia effect is achieved.
Patent Information
- Application Number
- CN202310969939.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-08-03
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2043-08-03
AI Technical Summary
Existing oral GLP-1 receptor agonist drugs are easily degraded in the stomach, resulting in low bioavailability and difficulty in effectively reducing blood sugar through oral routes. In addition, polypeptide biomacromolecule drugs have poor stability in the gastrointestinal absorption environment. Difficult to play a role.
Polyphenol organic compounds and polypeptide drugs are used to form a stable complex, improve the stability and absorption efficiency of the drug through hydrogen bond interaction, and prepare lyophilized powder by magnetic stirring and mixing method, and load it in enteric-coated capsules to improve oral biological treatment. Utilization.
It significantly improves the stability and absorption efficiency of the peptide drug, avoids stomach degradation, enhances oral bioavailability, achieves effective blood sugar-lowering effects, and simplifies the preparation process.
Smart Images

Figure CN117180405B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical preparations, and in particular to an oral hypoglycemic pharmaceutical preparation and a preparation method and application thereof. Background Art
[0002] Diabetes is a common clinical endocrine and metabolic disorder, characterized by high blood sugar, abnormal insulin secretion (fasting blood sugar ≥ 7.0mmol / L, glycosylated hemoglobin ≥ 6.5mmol / L or random blood sugar ≥ 11.1mmol / L) and easily accompanied by a variety of complications, which seriously hinder the daily life of diabetic patients. There are many types of diabetes. According to different pathogenesis, diabetes is divided into type 1 diabetes (Type 1 Diabetes Mellitus, T1DM), type 2 diabetes (Type 2 Diabetes Mellitus, T2DM), gestational diabetes and special types of diabetes. Nearly 10% of people in the world are threatened by diabetes every year, of which 90% to 95% are patients with type 2 diabetes (T2DM). According to the "Report on the Nutrition and Chronic Disease Status of Chinese Residents (2020)", the prevalence of diabetes in Chinese residents aged ≥ 18 years has reached 11.9%. At the same time, the incidence of diabetic diseases in men is higher than that in women, and the incidence of diseases in the middle-aged and elderly population is higher than that in the young population. China is dominated by type 2 diabetes (T2MD).
[0003] Glucagon-like peptide-1 (GLP-1) is an incretin secreted by intestinal L cells. GLP-1 can promote insulin secretion from pancreatic β cells in a glucose-dependent manner by binding to its receptor GLP-1R, inhibit glucagon secretion from pancreatic α cells, inhibit food intake, and delay gastric emptying. In addition, GLP-1 has a protective effect on organs or tissues such as the cardiovascular system, kidneys, and brain. Natural GLP-1 can be rapidly degraded by dipeptidyl peptidase 4 (DPP-4) and has an inactivation half-life of only 1 to 2 minutes, so its clinical application value is limited. Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a glucagon-like peptide-1 analog. Due to the change of part of the amino acid sequence, it can be protected from the rapid degradation of DPP-4. GLP-1 receptor agonists also inhibit glucagon secretion, promote insulin secretion, and inhibit pancreatic β-cell apoptosis in a glucose concentration-dependent manner. In addition to the significant blood sugar-lowering effect, it can also reduce weight, lower blood pressure, improve dyslipidemia, and reduce fatty liver. In particular, it has a protective effect on the heart and kidneys, and can reduce the risk of cardiovascular events. The emergence of GLP-1 receptor agonists has broadened the range of treatment options for patients with T2DM. It has become the most attractive drug for the treatment of type 2 diabetes because of its blood sugar-related hypoglycemic effect and the characteristics of protecting and repairing pancreatic β-cells. In the latest consensus document released by the Diabetes Association in 2020, GLP-1 receptor agonists are recommended for specific patients.
[0004] At present, there are 10 kinds of hypoglycemic drugs commonly used in clinical treatment, including injectable drugs: insulin and GLP-1 receptor agonists. Oral drugs: metformin, SGLT2 inhibitors, GLP-1 (Glucagon-like peptide-1, GLP-1) receptor agonists, sulfonylurea secretagogues, DPP4 inhibitors, α-glucosidase inhibitors, thiazolidinedione (Thiazolidinedione, TZD) and non-sulfonylurea (glinide) secretagogues. There are 10 GLP-1 receptor agonists approved for marketing worldwide, including 4 short-acting preparations that require daily injection (such as benaglutide, liraglutide, lixisenatide and exenatide), 5 long-acting preparations that require weekly injection (such as polyethylene glycol loxenatide, exenatide microspheres, dulaglutide, albiglutide and semaglutide (Semaglutide, SEM)), and a semaglutide tablet that requires daily oral administration. Except for albiglutide for injection, semaglutide injection and semaglutide tablets, which have not yet been launched in China, other FDA-approved GLP-1 receptor agonist drugs have entered the Chinese market. The world's first oral GLP-1 receptor agonist drug (Rybelsus) uses SNAC technology to achieve oral administration of semaglutide. SNAC, also known as sodium N-(8(2-hydroxybenzoyl)amino)octanoate, is a small molecule absorption enhancer. The combination of SNAC and semaglutide allows semaglutide to be partially absorbed in the stomach. SNAC can neutralize the low pH value of the microenvironment around the tablet, prevent gastric degradation, and cross the intestinal barrier through a transcellular pathway. When Rybelsus enters the blood, semaglutide and SNAC are easily dissociated. The dissolution of SNAC in the stomach can increase the pH of the local environment, which can not only improve the solubility of semaglutide, but also buffer the acidic environment in the stomach to resist degradation by gastric peptidases, and can play a hypoglycemic effect in a manner comparable to the efficacy of subcutaneous semaglutide. SNAC technology effectively improves the stability of semaglutide in the stomach and promotes intestinal absorption, allowing peptide drugs to enter the systemic circulation smoothly. However, the oral bioavailability of oral semaglutide is only about 1%, far less than subcutaneous injection. It needs to be administered once a day, with a dose of 7 or 14 mg per tablet. Food should not be taken 6 hours before and 0.5 hours after taking it, and the presence of nonspecific absorption enhancers can lead to potential adverse reactions.
[0005] In recent years, research on oral delivery of GLP-1 receptor agonists has made some progress. It is known that a pharmaceutical composition for oral GLP-1 administration comprising a tablet core and an immediate release coating (CN: 107205949A) is disclosed, wherein the tablet core comprises a GLP-1 peptide and an absorption enhancer; or a semaglutide oral microparticle preparation and a preparation method thereof (CN: 106924750A), wherein PEG is modified on semaglutide or carrier chitosan, and the drug and the carrier are prepared together as oral microparticles. Existing patented technologies overlap with original research patents, or PEGylation technology is used to improve stability. However, the above strategies cannot achieve the expected results. The development of oral preparations of protein peptide biopharmaceuticals has always been slow, and there is still a lot of room for improvement in drug research in the field of diabetes.
[0006] Insulin and other multi-protein polypeptide biomacromolecule drugs have unique advantages in the field of diabetes treatment, but due to their large molecular weight and unstable properties, they are limited by the harsh absorption environment of the gastrointestinal tract and are difficult to enter intestinal epithelial cells to exert their effects. The adjacent cells at the apical membrane of intestinal epithelial cells are tightly connected, which is a barrier to the intercellular transport pathway. A series of intracellular pathways will promote the entry of exogenous proteins into the lysosomal pathway, resulting in drug degradation, or the exogenous proteins will be sent back to the mucosal surface for luminal secretion instead of basolateral secretion, resulting in the inability of the drug to enter the circulatory system to exert its efficacy. Usually, biological drugs are used in clinical practice by subcutaneous injection. Long-term and frequent medication results in poor patient compliance and poor medication effect. Therefore, in order to alleviate the pain of patients and the inconvenience of frequent injections, it has been a hot topic for researchers to develop oral polypeptide hypoglycemic drug preparations with good therapeutic effect, high absorption efficiency, high bioavailability, simple preparation method, and stable properties to achieve in vivo delivery of biomacromolecule drugs. The research and development of non-injection routes of administration of protein peptide hypoglycemic drugs has long been a hot topic among pharmaceutical researchers at home and abroad. Oral administration has always been the main research direction because of its economy, convenience, and accurate dosage. Relatively speaking, oral administration is a more painless, convenient, relatively safe, and low-cost way of administration.
[0007] Polyphenol organic compounds have abundant aromatic rings and a large number of hydroxyl groups, and also have strong affinity for proteins and amino acids. Studies have shown that polyphenol organic compounds can form stable complexes with proteins, carbohydrates and lipids through non-covalent bonds such as hydrogen bonds, hydrophobic interactions, electrostatic interactions and covalent bond interactions in a wide pH range. The combination of natural polyphenols and proteins can improve the stability of proteins, inhibit protease activity, reduce protein digestion, thereby enhancing drug absorption, improving its oral bioavailability, and improving the therapeutic effect of polypeptides. Therefore, the complex formed by polyphenol organic compounds and polypeptides can be used as a biological drug oral drug delivery system with broad application prospects. Summary of the invention
[0008] The present invention aims to prepare an oral polypeptide hypoglycemic drug preparation which has simple process, safety, reliability, high compliance and good efficacy.
[0009] The present invention provides the following technical solutions:
[0010] A drug complex, characterized in that: the drug complex is a complex formed by a polypeptide drug and a polyphenol or by the interaction between hydrogen bonds, the polypeptide drug is semaglutide, and the polyphenol is tannic acid.
[0011] A drug complex, characterized in that the molar ratio of polyphenol to polypeptide is 1:1-50:1.
[0012] A freeze-dried drug powder, characterized in that the freeze-dried drug powder is a freeze-dried mixture containing the complex and a freeze-drying protectant.
[0013] The freeze-dried drug powder is characterized in that the freeze-drying protective agent includes sugars: glucose, sucrose, trehalose, lactose, maltose, fructan; glycerol, xylitol, sorbitol, mannitol, glycine, histidine, arginine and lysine.
[0014] A hypoglycemic drug enteric-coated capsule, characterized in that the capsule is composed of a preparation and an enteric-coated capsule shell; the preparation is composed of the freeze-dried drug powder.
[0015] The preparation method of the hypoglycemic drug enteric-coated capsule is characterized in that the steps are as follows:
[0016] 1) dissolving the polyphenol organic compound in water for later use;
[0017] 2) Dissolve the polypeptide drug in water for later use;
[0018] 3) stirring the polypeptide drug solution at a stirring speed of 800-1500 rpm, and simultaneously adding polyphenols for mixing;
[0019] 4) removing free polyphenolic organic compounds to obtain a complex formed by the polyphenolic organic compounds and protein polypeptides;
[0020] 5) adding a lyophilization protective agent to the suspension prepared in step 4), mixing well, placing in a glass bottle for precooling, and then freeze-drying to obtain a polyphenol-polypeptide freeze-dried powder;
[0021] 6) The freeze-dried powder obtained in step 5) is uniformly filled into enteric-coated capsule shells of a certain volume, thereby obtaining the oral polyphenol-polypeptide enteric-coated capsules of the present invention.
[0022] 6. The method for preparing the hypoglycemic drug enteric-coated capsule according to claim 5, characterized in that the steps are as follows:
[0023] 1) Weigh a certain amount of polyphenol organic compound and dissolve it in purified water for later use, with a concentration of 0.1 mg / mL-10 mg / mL;
[0024] 2) Weigh a certain amount of polypeptide hypoglycemic drugs and dissolve them in purified water for later use, with a concentration of 0.01 mg / mL to 5.0 mg / mL;
[0025] 3) The molar ratio of the polyphenol organic compound to the polypeptide hypoglycemic drug is 1:1-50:1; the polyphenol droplet addition rate is 0.5 mL / min to 5 mL / min.
[0026] 4) removing free polyphenols to obtain a complex formed by polyphenols and polypeptides;
[0027] 5) adding a lyophilization protective agent to the suspension prepared in step 4), mixing evenly, placing the mixture in a glass bottle for precooling, and then freeze-drying to obtain the lyophilized powder of the composite of the present invention; wherein the lyophilization protective agent is preferably one of glucose, sucrose, trehalose, lactose, and mannitol, or a combination of two or more thereof;
[0028] The freeze-drying conditions are as follows: the compound is pre-cooled at -20°C for 12-24 hours or at -80°C for 2-8 hours, and the freeze-drying time in a freeze dryer is 24-48 hours;
[0029] 6) The freeze-dried powder obtained in step 5) is evenly loaded into an enteric-coated capsule shell to obtain the oral polyphenol polypeptide hypoglycemic drug enteric-coated capsule of the present invention; the enteric-coated capsule shell material includes one or more of acrylic resin, cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PPVP), hydroxypropyl methylcellulose titanate (HPMCP), methyl methacrylate copolymer, etc.
[0030] As a further optimization method, the molar ratio of polyphenol organic compounds to polypeptide hypoglycemic drugs in step 3) is 1:1-50:1; when the ratio is greater than 50:1, insoluble particles will appear, and when it is less than 1:1, it is difficult to form a complex, and the preferred molar ratio is 3:1 as the best ratio. The polypeptide hypoglycemic drug solution is placed on a magnetic stirring device, a stirrer is added, and the stirring speed is 800-1500rpm. At the same time, under magnetic stirring conditions, polyphenols are slowly added to the polypeptide hypoglycemic drug solution, and the drop speed is 0.5mL / min to 5mL / min. After the drop addition is completed, magnetic stirring is performed for half an hour to three hours to successfully obtain a complex.
[0031] As a further optimization method, a drug complex lyophilized powder in step 5) is characterized in that the lyoprotectant includes carbohydrates: the most commonly used excipients in lyophilized products, the hydroxyl groups in its structure can replace the hydrogen bonds between proteins and water to provide a stabilizing effect, specifically: glucose, sucrose, trehalose, lactose, maltose and fructans, etc.; polyols: stabilize proteins through their hydroxyl groups and serve as fillers, specifically: glycerol, xylitol, sorbitol and mannitol, etc.; amino acid ions: have acid-base properties and can inhibit the pH change of the solution during the low-temperature storage and freeze-drying process of biological products, thereby achieving the purpose of protecting active components, specifically: glycine, histidine, arginine and lysine, etc.; salts: mainly used as buffers to balance the pH value during freeze-drying storage, specifically pH buffers.
[0032] Specifically, the freeze-dried powder has the appearance of white powder, is porous, loose, and needle-shaped, has good formability, and its volume remains unchanged before and after freeze-drying.
[0033] As a further optimization method, in step 6), the present invention also provides an application of loading the above-mentioned lyophilized powder of the complex into enteric-coated capsules. The oral polyphenol-polypeptide enteric-coated capsules of the present invention include a preparation body and an enteric-coated capsule shell. The preparation body includes a drug complex and a lyophilization protective agent. The drug complex is an oral polyphenol organic compound-polypeptide complex with a hypoglycemic effect. The lyophilization protective agent is one, two or more protective agents that can stabilize protein or polypeptide drugs. The oral polyphenol-polypeptide enteric-coated capsules are prepared by loading a certain volume of lyophilized powder of the polyphenol-polypeptide complex, and the lyophilized powder of the polyphenol-polypeptide complex is obtained by lyophilizing the drug complex.
[0034] The enteric material of the enteric capsule shell is a material that is insoluble under gastric acid conditions and begins to dissolve in the intestinal fluid environment; it includes but is not limited to one or more of acrylic resin, cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PPVP), hydroxypropyl methylcellulose titanate (HPMCP), methyl methacrylate copolymer, etc.
[0035] The enteric-coated capsule is used in an oral preparation for lowering blood sugar.
[0036] The polypeptide hypoglycemic drug Semaglutide (Semaglutide, SEM) involved in the present invention is a long-acting glucagon-like peptide-1 receptor agonist with a molecular weight of 4113 and a structural formula as follows: Figure 1Semaglutide has a longer fatty chain and increased hydrophobicity, but after short-chain PEGylation modification, its hydrophilicity is enhanced. It can not only bind tightly to albumin and cover the DPP-4 enzyme hydrolysis site, but also reduce renal excretion, prolong the biological half-life, and achieve a long circulation effect. Semaglutide is often used to treat type 2 diabetes because it can safely and effectively improve blood sugar, reduce weight, and reduce the risk of cardiovascular, renal and hypoglycemic events in diabetic patients.
[0037]
[0038] Semaglutide structure
[0039] The polyphenolic drug tannic acid (TA) involved in the present invention is a natural polyphenol with a molecular weight of 1701 and a structural formula as follows: Figure 2 TA is rich in hydroxyl groups (3 -OH groups attached to an aromatic ring) and catechol groups (2 -OH groups covalently linked to an aromatic ring). TA is widely found in edible plants, has antioxidant activity, can bind to proteins or peptides, and has potential functions such as lowering blood pressure, lowering blood lipids, and regulating immune responses.
[0040]
[0041] Tannic acid structure
[0042] Principle of the invention:
[0043] The present invention adopts a magnetic stirring mixing method, and combines polyphenols and polypeptides in a specific ratio (molar ratio of 1:1-50:1) through the mechanism of hydrogen bond interaction to prepare a stable and efficient oral polyphenol organic compound-polypeptide complex. Polyphenol compounds can produce strong interactions with proteins, and polyphenols with a large number of hydroxyl groups have a strong affinity for biological macromolecules, and can form strong hydrogen bonds with compounds with carboxyl groups, or hydrogen atoms in polyphenols interact with electronegative ions such as N, O, or S in polypeptides to form hydrogen bonds, thereby further enhancing drug stability.
[0044] Beneficial Effects
[0045] 1. The oral polyphenol organic compound and polypeptide complex prepared by the present invention has the following beneficial effects:
[0046] (1) A preparation method without absorption enhancers is adopted, and a magnetic stirring mixing method is used to combine polypeptides and polyphenols in a specific ratio through the mechanism of hydrogen bond interaction, thereby avoiding adverse reactions caused by nonspecific absorption enhancers.
[0047] (2) Polyphenolic organic compounds have rich aromatic rings and a large number of hydroxyl groups. They not only have a strong affinity for proteins and amino acids, but also have pharmacological effects of antioxidant, digestive, and lipid-lowering effects, which can enhance the therapeutic effect of semaglutide peptide hypoglycemic drugs.
[0048] (3) Polyphenol organic compounds and polypeptides can help improve the stability of polypeptide hypoglycemic drugs and maintain their activity through hydrogen bonding. The hydrogen atoms in polyphenol organic compounds interact with electronegative ions such as N, O, or S in polypeptides to form hydrogen bonds.
[0049] (4) Although the polyphenol organic compound and the polypeptide form a stable complex, the complex of the present invention can still have a high release rate in simulated gastric fluid and simulated intestinal fluid. In animal experiments, the present invention is administered by duodenal injection, bypassing the stomach and directly reaching the small intestine, the absorption site, avoiding the acidic environment of the stomach and the destruction of the drug by digestive enzymes, effectively promoting the absorption of oral drugs such as semaglutide and insulin, and improving the bioavailability of oral insulin.
[0050] (6) The oral polyphenol-polypeptide complex prepared by the present invention has good safety and stability, and can be subsequently freeze-dried. Specifically, compared with other drying methods, drug freeze-drying technology has the following advantages: 1) Drugs are dried at low temperatures without denaturation or loss of biological activity. This is particularly applicable to the preservation of heat-sensitive drugs, such as protein drugs, polypeptides, vaccines, and blood products; 2) The loss of volatile components and nutrients that are easily denatured by heat in drugs is very small; 3) The growth of microorganisms and the action of enzymes in drugs are almost impossible; 4) After freeze-drying, the drug can best maintain its original volume and shape; when re-dissolved, the contact surface with water is large, it can be quickly restored, and the original shape can be maintained; 5) The drug is dried under vacuum, and there is very little oxygen in the environment, so the easily oxidized substances in the drug can be protected; 6) 95% or more of the water in the drug can be removed, which is convenient for transportation and long-term storage; 7) Freeze-dried drugs can be stored for a long time at room temperature or in a refrigerator.
[0051] (7) The preparation is finally prepared into oral enteric-coated capsules, which have a simple preparation method, are insoluble in the stomach and enteric-coated, and can be released in a targeted manner, thereby enhancing drug uptake and intestinal absorption, thereby improving drug bioavailability and having a better hypoglycemic effect.
[0052] (8) Oral preparations have strong core competitiveness, are easier to store and transport, have strong patient compliance, have great competitive advantages in digestive system medications, and have very broad development prospects.
[0053] 2. The composite of the present invention screens the prescription ratio of polyphenol organic compounds to polypeptides by fluorescence emission spectrum and circular dichroism spectrum. Fluorescence emission spectrum can show the environment of fluorescent groups in protein and polypeptide molecules, so as to study the conformational changes of proteins and intermolecular interactions. The structure of polypeptide drugs contains tryptophan residues, which produce maximum fluorescence intensity at an emission wavelength of 340nm under the condition of excitation wavelength of 295nm. When polypeptide drugs are combined with tannic acid, fluorescence quenching occurs to varying degrees. CD spectrum is the most widely used method for determining protein conformation. Since the structure of polypeptide drugs contains α-helix and β-fold, there are two broad negative peaks at 208nm and 222nm. As the dosage of tannic acid increases, the negative peak intensity at 208nm-222nm decreases to varying degrees, indicating that the drug interacts with tannic acid to change its secondary structure. Based on the two spectra and the results of encapsulation rate and drug loading determination, the interaction between polyphenols and polypeptide drugs is strongest when the molar ratio of polyphenol organic compounds to polypeptide hypoglycemic drugs is 3:1, so the preferred molar ratio is 3:1.
[0054] 3. This study enriches the research on the interaction between proteins and polyphenols, and will be conducive to the development of tannic acid-protein complexes as carriers for oral drug delivery systems. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] Figure 1 This is the ultraviolet absorption spectrum of the semaglutide tannic acid complex prepared in Preparation Example 1 of the present invention.
[0056] Figure 2 This is a fluorescence emission spectrum of the semaglutide tannic acid complex prepared in Preparation Example 1 of the present invention.
[0057] Figure 3 This is a circular dichroism spectrum of the semaglutide tannic acid complex prepared in Preparation Example 1 of the present invention.
[0058] Figure 4 This is a graph showing the encapsulation efficiency and drug loading measurement results of the semaglutide tannic acid complex prepared in Preparation Example 1 of the present invention.
[0059] Figure 5 This is a scanning electron microscope image of the semaglutide tannic acid complex prepared in Preparation Example 3 of the present invention.
[0060] Figure 6 This is a graph showing the hypoglycemic effect of oral administration of the semaglutide tannate complex prepared in Preparation Example 1 of the present invention to rats. The black curve is the semaglutide solution oral control group, and the red curve is the semaglutide tannate complex administration group.
[0061] Figure 7This is a graph showing the results of a cytotoxicity experiment of the semaglutide tannic acid complex prepared in Example 1 of the present invention.
[0062] Figure 8 This is a graph showing the results of a Caco-2 cell uptake experiment of the semaglutide tannic acid complex prepared in Example 1 of the present invention.
[0063] Fig. 9 This is a graph showing the release results of semaglutide in the semaglutide tannic acid complex in simulated gastric fluid prepared in Example 1 of the present invention.
[0064] Fig.10 This is a graph showing the release results of semaglutide in the semaglutide tannic acid complex in simulated intestinal fluid prepared in Example 1 of the present invention.
[0065] Fig.11 This is the blood drug concentration-time curve of the semaglutide tannic acid complex in the pharmacokinetic experiment prepared in Example 1 of the present invention.
[0066] Fig.12 This is a graph showing the encapsulation efficiency and drug loading measurement results of the semaglutide tannic acid complex freeze-dried powder prepared in Preparation Example 11 of the present invention.
[0067] Fig.13 This is a graph showing the cumulative release results of the oral semaglutide tannate enteric-coated capsules prepared in Example 12 of the present invention in simulated gastric fluid and simulated intestinal fluid.
[0068] Fig.14 This is the blood drug concentration-time curve of the oral semaglutide tannate enteric-coated capsules in the pharmacokinetic experiment in Example 12 of the present invention. DETAILED DESCRIPTION
[0069] The raw materials or reagents used in the present invention are all commercially available. The composite is characterized by using an ultraviolet spectrophotometer, a fluorescence spectrophotometer, a circular dichroism spectrometer, etc., and the hypoglycemic effect, bioavailability and absorption of the composite are evaluated by animal experiments. The present invention uses polyphenol organic compounds to interact with polypeptides to form a composite as an oral delivery system for oral biomacromolecule drugs.
[0070] Example 1 Preparation and characterization of oral semaglutide tannic acid complex:
[0071] Tannic acid (TA) and semaglutide (SEM) were weighed and dissolved in purified water respectively, and mixed in a molar ratio of 1:1-10:1. The concentration of semaglutide was 0.275 mg / ml, and the concentrations of tannic acid were 0.11 mg / ml, 0.22 mg / ml, 0.32 mg / ml, 0.43 mg / ml, 0.53 mg / ml, 0.66 mg / ml, 0.77 mg / ml, 0.88 mg / ml, 0.99 mg / ml, and 1.1 mg / ml, respectively. The semaglutide solution was placed on a magnetic stirring device, a stirring bar was added, and the stirring speed was 1000 rpm. After the semaglutide was completely dissolved, the tannic acid solution was slowly added dropwise to the semaglutide solution under magnetic stirring at a dropping speed of 2 mL / min. After the dropping was completed, a milky white solution was formed after two hours of magnetic stirring, and the tannic acid semaglutide (TA / SEM) peptide complex was successfully obtained. After the preparation is completed, free tannic acid is removed by ultrafiltration using an Ultra-410 kDa ultrafiltration tube, and the purified complex fraction on the upper layer of the ultrafiltration tube is collected.
[0072] Prescription and dosage of semaglutide tannic acid complex:
[0073]
[0074] The prepared composite was characterized by ultraviolet spectrophotometry, fluorescence spectrophotometry and circular dichroism. Figure 1 The UV-visible absorption spectra of semaglutide, tannic acid, the physical mixture of tannic acid and semaglutide, and the tannic acid-semaglutide complex in the wavelength range of 200nm-600nm. Figure 1 As shown in the figure, free semaglutide has a strong UV absorption peak at an absorption wavelength of 274 nm. When the complex is formed, semaglutide combines with tannic acid, and the peak shape and intensity of its UV absorption peak at 250-300 nm change, with a red shift and enhanced absorbance, indicating the successful preparation of the complex. Figure 2 The fluorescence emission spectra of the complex of semaglutide and tannic acid semaglutide at different prescription ratios are shown in Figure 2. Fluorescence spectroscopy is widely used in protein conformation studies. Proteins can emit endogenous fluorescence in a certain wavelength region because there are a large number of tryptophan residues inside ordinary protein molecules, and the change in fluorescence intensity directly reflects the changes in Try itself and the surrounding hydrophobic environment in the protein. Therefore, by measuring the change in fluorescence intensity of semaglutide after semaglutide forms a complex with tannic acid, the interaction principle and intensity between the drug and tannic acid can be simply analyzed. From the experimental results, it can be seen that with the increase in the proportion of tannic acid, the fluorescence of semaglutide is quenched to varying degrees, indicating the interaction between tannic acid and semaglutide, and it can be preliminarily judged that the complex is successfully prepared. Figure 3This is the circular dichroism spectrum of the tannic acid semaglutide complex. Circular dichroism is mainly used to determine the spatial structure of proteins, and mainly reflects the interaction between drugs and proteins through changes in the spatial structure of proteins; the circular dichroism spectrum in the far-ultraviolet wavelength range (190nm-250nm) represents the changes in the secondary structure of proteins. Compared with the pure drug, the conformation of semaglutide in the complex has changed due to the addition of tannic acid, which further confirms the formation of the complex.
[0075] Based on the results of the three spectra, when the molar ratio of polyphenol organic compounds to polypeptide hypoglycemic drugs is 3:1, the fluorescence quenching of polypeptide drugs is the strongest, the intensity of the wider negative peaks of α-helix and β-fold decreases significantly, the interaction between polyphenols and polypeptide drugs is the strongest, and the drug loading capacity is the highest, so the preferred molar ratio is 3:1 as the best ratio.
[0076] Example 2 Determination of encapsulation efficiency and drug loading of semaglutide tannic acid complex
[0077] In order to investigate the encapsulation efficiency and drug loading of the tannic acid semaglutide complex, ultrafiltration centrifugation was used to separate the free drug in the preparation, and high performance liquid chromatography was used to determine the content of free drug. The specific steps are: accurately measure 2 ml of the complex solution in Example 1 in an ultrafiltration tube, centrifuge at 3500 rpm for 15 min, take 20 μL of the ultrafiltrate for injection, determine the content of free semaglutide by high performance liquid chromatography, and calculate the total drug content of the complex preparation by peak area. The encapsulation efficiency and drug loading of the complex were calculated according to the following formulas.
[0078] Encapsulation efficiency (%) = (1-amount of semaglutide in supernatant / total amount of semaglutide) × 100%
[0079] Drug loading (%) = amount of semaglutide encapsulated in the complex / total amount of carrier × 100%
[0080] like Figure 4 The results showed that the oral tannic acid semaglutide complex had a high encapsulation rate and drug loading capacity. When the ratio of tannic acid to semaglutide was 3:1, the drug loading capacity and encapsulation rate were very high, at 80.74%, and the encapsulation rate of semaglutide was 56.44%.
[0081] Calculation results of drug loading and encapsulation efficiency of TA / SEM complexes with different formulation ratios:
[0082]
[0083] Example 3 Scanning electron microscopy observation of tannic acid semaglutide complex
[0084] Referring to the optimal prescription ratio of Example 1, that is, the molar ratio of polyphenol organic compounds to polypeptide hypoglycemic drugs was 3:1, a semaglutide tannic acid complex was prepared. Using the same concentration of free SEM aqueous solution as a control, the complex and the SEM aqueous solution were diluted to an appropriate concentration, dropped on a silicon wafer and dried naturally, the silicon wafer was fixed on a sample plate with conductive glue, gold was sprayed under vacuum for 200 seconds, and photographed using a scanning electron microscope at an emission voltage of 10 kV.
[0085] The scanning electron microscopy results are as follows Figure 5 As shown, the results showed that compared with the control group (free SEM), the preparation group (TA / SEM complex) presented a dense cross-linked network structure, which was beneficial to the encapsulation of the drug and the stability of the complex.
[0086] Example 4 Evaluation of the hypoglycemic effect of oral semaglutide tannic acid complex
[0087] Four normal male Sprgue-dawley rats were weighed and randomly divided into two groups (n=2). They were fasted for 12 hours before administration and had free access to water. The first group was the control group of the raw material drug, and the same volume of raw material drug solution was given by enteral injection; the second group was the medium-dose group (0.63 mg / kg) of TA / SEM complex administered by enteral injection; the experimental group rats were given the drug at 0h. The tails of the rats in each group were cut and blood was collected at 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, and 24h, and the blood sugar level was measured with a blood glucose meter, and the hypoglycemic effect of each group was statistically analyzed.
[0088] The hypoglycemic effect was evaluated based on the percentage change of blood glucose level at each time point relative to the initial value, and the blood glucose concentration at 0 h was taken as 100%, and the blood glucose relative concentration-time change curve was drawn. Figure 6 As shown, compared with the raw material control group (control group curve), the oral TA / SEM complex group (preparation group curve) has a significant effect on lowering blood sugar. It begins to significantly reduce blood sugar in rats 2 hours after administration, and the drug effect can last for more than 10 hours.
[0089] Example 6 Cytotoxicity test of semaglutide tannic acid complex
[0090] The cytotoxicity of different concentrations of tannic acid semaglutide complexes was determined by MTT method. Caco-2 cells in the logarithmic growth phase were digested with trypsin and centrifuged and counted. They were seeded in 96-well culture plates at a density of 3000 cells per well, and the culture plates were placed in an incubator for 24 hours to allow the cells to adhere to the wall. After 24 hours, the culture medium in the culture plate was discarded, and 180 μl of high-glucose DMEM blank culture medium and 20 μl of various preparations of different concentrations were added to each well, where the final concentration of semaglutide was 15, 30, 50, 100, 150, 200, 250, 300 μg / ml. Five replicate wells were set for each sample, and zero wells and control wells were set at the same time. The cells were placed in an incubator and cultured for 4 h. The incubation medium was discarded, and 20 μl of 5 mg / ml MTT solution was added to each well. The cells were cultured for 4 h. The culture medium was discarded, and 200 μl of DMSO solution was added to each well. The cells were placed on a shaker and shaken at a low speed for 10 min. The absorbance at 570 nm was measured with a microplate reader. The cell survival rate of each well was calculated according to the following formula.
[0091] Cell survival rate (%) = (absorbance of drug group - absorbance of blank group) / (absorbance of control group - absorbance of blank group) × 100%
[0092] Results Figure 7 As shown, the cell viability was higher than 75%, which indicated that the TA / SEM complex had low toxicity to Caco-2 cells and had good safety.
[0093] Example 7 Cellular uptake experiment of semaglutide tannic acid complex
[0094] Caco-2 cells with good growth status were digested and resuspended in fresh medium at 2×10 5 The cells were inoculated at a density of 10 cells / well in a confocal culture dish, and 1 ml of culture medium was added. After overnight culture, the culture medium was discarded, and a tannic acid semaglutide complex preparation (containing the fluorescent marker rhodamine B isothiocyanate (RITC)) was added. The cells were incubated in a serum-free culture medium at 37°C for 4 hours, and the fluorescent solution was discarded. The cells were washed three times with PBS, and 1 mL of immunofluorescence fixative was added. The cells were fixed at room temperature for 10 minutes, and the fixative was discarded. The cells were washed three times with PBS, and 1 mL of DAPI staining solution was added. The cells were stained at room temperature for 10 minutes, and the staining solution was discarded. The cells were washed three times with PBS, and finally 150 μl of PBS was added. The cells were placed under a laser confocal microscope and photographed to observe the cell uptake in each group.
[0095] Results Figure 8 As shown, the semaglutide tannate complex formulation was taken up by Caco-2 cells over time.
[0096] Example 8 In vitro release experiment of semaglutide tannic acid complex
[0097] The in vitro release properties of the tannic acid semaglutide complex were investigated by the dialysis bag method. The semaglutide in Example 1 was replaced by semaglutide (SEM-RITC) combined with a fluorescent marker (RITC), and prepared according to the optimal prescription ratio of Example 1. 1 ml of the complex preparation was accurately measured and transferred to a MWCO 8000Da dialysis bag, and oscillated in a water bath in 30 ml of release medium at 37±2°C and a rotation speed of 120 rpm. The release medium was simulated gastric fluid and simulated intestinal fluid, with pH values of 1.2 and 6.8, respectively. At 0.5h, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h and 72h, 1 mL of the release sample was taken out of the dialysis bag, and an equal volume of fresh release medium was added. The content of the released fluorescently labeled semaglutide was determined by a fluorescence spectrophotometer, and the cumulative release percentage was calculated.
[0098] The results are shown in Figures 9 and 10, indicating that the semaglutide tannate complex has no sustained-release effect in the stomach but is slowly released in the intestine.
[0099] Example 9 Pharmacokinetics of Semaglutide Tannic Acid Complex
[0100] Eighteen normal adult male Sprgue-dawley rats were weighed and randomly divided into three groups (n=6). The rats were fasted for more than 12 hours before administration and had free access to water.
[0101] Group 1: control group, enteral administration of SEM-RITC group (1.26 mg / kg);
[0102] Group 2: Preparation group, enteral administration of TA / SEM-RITC (1.26 mg / kg);
[0103] Group 3: subcutaneous group, subcutaneous injection of SEM-RITC group (0.045 mg / kg);
[0104] The rats in the experimental group were given the drug at 0h. The rats in each group were blooded from the orbit at 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 24h, and 36h, respectively. The blood samples (0.3ml) were collected from the ophthalmic vein and placed in a 1.5ml centrifuge tube moistened with 3.8% sodium citrate. The centrifuge tube was shaken and centrifuged (3300rpm, 10min), the upper plasma was aspirated and stored in a -80℃ refrigerator, and the fluorescent drug content was determined by a multifunctional microplate reader.
[0105] like Fig.11As shown, the pharmacokinetic experimental data showed that compared with the subcutaneous injection of the raw material drug, the bioavailability of the subcutaneous group was 100%, the relative bioavailability of the preparation group was 3.5 times that of the control group, the relative bioavailability of the control group was 4.1%, and the relative bioavailability of the preparation group was 14.64%. The preparation significantly improved the bioavailability of the drug.
[0106] Pharmacokinetic parameters of the control group, preparation group and subcutaneous group in rats:
[0107] Formulations AUC (μg·h / L) <![CDATA[t 1 / 2 (h)]]> Tmax(h) Cmax(μg / L) <![CDATA[B R (100%)]]> Control group 4053.70±179.73 25.10±11.73 4.08±1.83 252.82±28.90 4.10 Preparation group 14623.04±3033.60 16.07±1.48 7.33±0.94 787.762±96.14 14.64 Subcutaneous group 59903.13±2076.28 7.80±1.81 5.50±1.12 3778.832±158.99 100
[0108] Example 10 One-way in vivo intestinal perfusion experiment of semaglutide tannic acid complex
[0109] Rats weighing 220±20g were selected, anesthetized by intraperitoneal injection of chloral hydrate (3.3%, 1ml / 200g), fixed on a mouse board in dorsal position, and a longitudinal incision of about 3cm was made along the midline of the abdomen. The intestine was carefully peeled out, and the incision was made at both ends of the 10cm section below the pylorus (jejunum) and cannulated and ligated. A one-way perfusion method was adopted, and the contents were quickly flushed out with KR solution from top to bottom, and then the preparation diluent containing fluorescent markers diluted with KR solution was perfused at a flow rate of 0.2mL / min. After 30min of equilibrium, 2mL of effluent was collected every 10min until 120min. After the perfusion was completed, the fluorescence intensity of each sample was measured.
[0110] The data of the one-way in vivo intestinal perfusion experiment in rats showed that compared with the oral raw material drug group, the drug absorption rate constant (Ka) of the preparation group was about twice that of the control group, and the drug apparent absorption coefficient (Papp) of the preparation group was about twice that of the control group. The preparation significantly improved the drug absorption rate constant and the drug apparent absorption coefficient.
[0111]
[0112] Example 11 Determination of encapsulation efficiency and drug loading of semaglutide tannic acid complex freeze-dried powder
[0113] In order to investigate the encapsulation efficiency and drug loading of enteric-coated capsules, free drugs in the preparations were separated by ultrafiltration centrifugation, and the content of free drugs was determined by HPLC.
[0114] The specific steps are as follows: weigh tannic acid and semaglutide and dissolve them in purified water respectively, mix them in a molar ratio of 3:1, the concentration of semaglutide is 0.25mg / ml, and the concentration of tannic acid is 1.24mg / ml; place the semaglutide solution on a magnetic stirring device, add a stirrer, and stir at a speed of 1000rpm. After the semaglutide is completely dissolved, slowly add the tannic acid solution to the semaglutide solution under magnetic stirring at a rate of 0.5mL / min. After the addition is completed, a milky white solution is formed after two hours of magnetic stirring, and the tannic acid semaglutide complex is successfully obtained. After the preparation is completed, a certain amount of mannitol is weighed as a freeze-drying protective agent and dissolved in the obtained complex, with concentrations of 0.2, 1, 2, and 5mg / mL, respectively, and mixed evenly. The obtained suspension is placed in a freeze-drying bottle and pre-frozen at -80℃ for 4 hours, and freeze-dried for 48 hours to obtain a freeze-dried powder of the tannic acid semaglutide complex. Accurately weigh the lyophilized powder of the complex and dissolve it in 5 ml of purified water. Centrifuge at 4000 rpm for 10 min. Take 20 μL of the lower filtrate for injection. Determine the content of free semaglutide by high performance liquid chromatography. Calculate the total drug content of the complex preparation by peak area. Calculate the encapsulation efficiency and drug loading of the lyophilized powder according to the following formulas.
[0115] Encapsulation efficiency (%) = (1-free semaglutide amount / total semaglutide amount) × 100%
[0116] Drug loading (%) = amount of semaglutide encapsulated in the complex / total amount of drug × 100%
[0117] like Fig.12 The results showed that the encapsulation efficiency and drug loading of semaglutide tannic acid complex freeze-dried powder gradually decreased with the increase of the amount of lyoprotectant added, and the encapsulation efficiency was less affected.
[0118] Calculation results of drug loading and encapsulation efficiency of semaglutide tannate oral enteric-coated capsules with different amounts of lyophilization protectants added:
[0119] Mannitol dosage (mg / mL) 0.2 1 2 5 Encapsulation rate (%) 43.90 44.93 39.00 38.02 Drug loading (%) 17.25 7.75 3.45 1.61
[0120] Example 12 Preparation of Semaglutide Tannic Acid Oral Enteric-coated Capsules
[0121] The present invention provides a preparation process of semaglutide tannate oral enteric-coated capsules, comprising the following steps: preparing semaglutide tannate complex freeze-dried powder by freeze-drying technology according to Example 11, and uniformly filling the obtained freeze-dried powder into enteric-coated capsule shells of a certain volume to obtain oral polyphenol-polypeptide enteric-coated capsules.
[0122] Prescription and dosage of semaglutide tannate oral enteric-coated capsules:
[0123] Semaglutide 1mg Tannic acid 1.24mg Mannitol 1, 5, 10, 25 mg
[0124] Example 13 Determination of in vitro dissolution of semaglutide tannic acid oral enteric-coated capsules
[0125] According to the first method of dissolution and release determination method 0931 of the fourth general rule of the 2020 edition of the Chinese Pharmacopoeia: basket method, the drug release characteristics of enteric-coated capsules were evaluated. According to the basket method, 300 mL of degassed dissolution medium was injected into each operating container. The dissolution medium was simulated gastric fluid and simulated intestinal fluid, with pH values of 1.2 and 6.8, respectively. The temperature was controlled at (37±0.5)℃, and the speed was adjusted to 100r / min. Take 6 capsules of this product, use a sinker basket, and put the capsules into the specified sinker baskets respectively, so that the capsules are completely sunk into the dissolution medium, and start the machine immediately. When the dissolution medium is acid, sample 4 mL at 5, 15, 30, 45, 60, 90, and 120 minutes, and add an equal volume of dissolution medium, and filter with a 0.45μm microporous membrane. After two hours, the acid solution in each dissolution cup was discarded, and phosphate buffer (pH 6.8) at a temperature of 37°C ± 0.5°C was immediately added. 4 mL of samples were taken at 5, 10, 15, 30, 45, 60, 90, and 120 min, and an equal volume of dissolution medium was added, and filtered through a 0.45 μm microporous membrane. The filtrate obtained at each time point was determined by high performance liquid chromatography, the solubility was calculated, and the dissolution curve was drawn, as shown in FIG. Fig.13 .
[0126] The results showed that the enteric-coated capsules prepared according to the optimal prescription released almost no substance in artificial gastric juice for 2 hours, with a cumulative release of less than 10%. The solubility in artificial intestinal juice at 45 minutes exceeded 70% of the labeled amount, which was in line with the pharmacopoeia requirements.
[0127] Example 14 Pharmacokinetics of Semaglutide Tannic Acid Oral Enteric-coated Capsules
[0128] Fifteen normal adult male Sprgue-dawley rats were weighed and randomly divided into three groups (n=5). The rats were fasted for more than 12 hours before administration and had free access to water.
[0129] Group 1: intravenous injection of free SEM (0.045 mg / kg);
[0130] Group 2: subcutaneous injection of free SEM (0.045 mg / kg);
[0131] Group 3: oral administration of TA / SEM enteric-coated capsules (1.26 mg / kg);
[0132] The rats in the experimental group were administered at 0h. Blood was collected from the eye sockets of the rats in each group at 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 24h, and 36h, respectively. Blood samples (0.5ml) were collected from the ophthalmic vein and placed in a 1.5ml centrifuge tube moistened with 3.8% sodium citrate. The centrifuge tube was shaken and centrifuged (3000rpm, 10min), and the upper plasma was aspirated and stored in a -80℃ refrigerator. The drug content was determined by LC-MS.
[0133] like Fig.14 As shown in the figure, the pharmacokinetic experimental data showed that the absolute bioavailability of the preparation group was 4.37% compared with the intravenous injection of the raw material drug, and the relative bioavailability of the preparation group was 3.83% compared with the subcutaneous injection of the raw material drug. The oral administration dose increased by 30 times, which is equivalent to the injection administration.
[0134] Pharmacokinetic parameters of intravenous, subcutaneous and oral groups in rats:
[0135] Formulations AUC0-t (μg / ml*h) AUC0-∞(μg / ml*h) <![CDATA[t 1 / 2 (h)]]> Tmax(h) Cmax(ug / ml) Intravenous group (SEM) 26.85±5.55 89.63±24.49 69.51±8.59 4.3±1.43 1.65±0.43 Subcutaneous group (SEM) 30.66±7.81 149.08±15.96 126.35±50.90 4.7±1 1.59±0.20 Oral group (TA / SEM) 32.86±6.70 76.19±8.06 47.35±16.26 6.8±0.94 1.71±0.37
Claims
1. A hypoglycemic drug enteric-coated capsule, characterized in that: The capsule is composed of freeze-dried drug powder and an enteric-coated capsule shell; the freeze-dried drug powder is a freeze-dried mixture of a drug complex and a freeze-dried protective agent; The drug complex is a complex formed by the interaction between a polypeptide and a polyphenol through hydrogen bonds, wherein the polypeptide is semaglutide and the polyphenol is tannic acid; wherein the molar ratio of the polyphenol to the polypeptide is 3:1; the lyophilization protective agent is mannitol; and the hypoglycemic drug enteric-coated capsule is prepared by the following steps: 1) dissolving the polyphenol organic compound in water for later use; 2) Dissolve the polypeptide drug in water for later use; 3) stirring the polypeptide drug solution at a stirring speed of 800-1500 rpm, and simultaneously adding polyphenols for mixing; 4) removing free polyphenolic organic compounds to obtain a complex formed by the polyphenolic organic compounds and protein polypeptides; 5) adding a lyophilization protective agent to the suspension prepared in step 4), mixing evenly, placing in a glass bottle for precooling, and then freeze-drying to obtain a polyphenol-polypeptide freeze-dried powder; 6) The freeze-dried powder obtained in step 5) is evenly filled into the shell of the enteric-coated capsule to obtain the enteric-coated capsule.
2. The hypoglycemic drug enteric-coated capsule according to claim 1, characterized in that: The hypoglycemic drug enteric-coated capsule is prepared by the following steps: 1) Weigh polyphenolic organic compounds and dissolve them in purified water for later use, with a concentration of 0.1 mg / mL-10 mg / mL; 2) Weigh the polypeptide hypoglycemic drug and dissolve it in purified water for later use, with a concentration of 0.01 mg / mL to 5.0 mg / mL; 3) The molar ratio of polyphenol organic compounds to polypeptides is 3:1; the polyphenol droplet addition rate is 0.5 mL / min to 5 mL / min; the polypeptide solution is in a stirring system at 800-1500 rpm; 4) removing free polyphenols to obtain a complex formed by polyphenols and polypeptides; 5) adding a lyophilization protective agent to the suspension prepared in step 4), mixing evenly, placing the mixture in a glass bottle for precooling, and then freeze-drying to obtain a lyophilized powder of the complex; wherein the lyophilization protective agent is mannitol; and the freeze-drying conditions are that the complex is precooled at -20°C for 12-24 hours or at -80°C for 2-8 hours, and placed in a freeze dryer for freeze drying for 24-48 hours; 6) The freeze-dried powder obtained in step 5) is evenly filled into an enteric-coated capsule shell to obtain the hypoglycemic drug enteric-coated capsule; the enteric-coated capsule shell material includes one or more of acrylic resin, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose titanate, and methyl methacrylate copolymer.
3. Use of the hypoglycemic drug enteric-coated capsule according to claim 1 or 2 in the preparation of hypoglycemic drugs.
